scholarly journals Data Acquisition and Software for the ATLAS Tile Calorimeter Phase-II Upgrade Demonstrator

2019 ◽  
Vol 214 ◽  
pp. 01004 ◽  
Author(s):  
Xiaoguang Yue

After a series of upgrades, the High Luminosity LHC (HL-LHC) will have an instantaneous luminosity of 5-7 times larger than the LHC design value. The readout electronics of the ATLAS Tile Calorimeter (TileCal) will undergo a substantial upgrade during the Phase-II upgrade to accommodate the HL-LHC requirements. After the Phase-II upgrade, the TileCal detector signals will be digitized by on-detector electronics and transferred to the the TileCal PreProcessors (TilePPr), which is a part of the off-detector electronics. In the TilePPr, the digitized data will be stored in pipeline buffers and be packed and readout to the Front-End Link eXchange (FELIX) system upon receiving a trigger decision. At the same time, the energy information will be reconstructed from the detector data and transferred to the Level-1 Calorimeter Trigger (L1Calo) system in different granularity for every bunch crossing. The TileCal Demonstrator is designed to evaluate the performance of the TileCal with new readout electronics without compromising the present data taking. This contribution describes in detail the data processing and the hardware, firmware, software components of the TileCal Demonstrator system, together with the results of beam tests performed at CERN.

Author(s):  
Barbara Clerbaux ◽  
Marta Colomer Molla ◽  
Pierre-Alexandre Petitjean ◽  
Yu Xu ◽  
Yifan Yang

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 57-57
Author(s):  
Hideaki Bando ◽  
Daisuke Kotani ◽  
Masahito Kotaka ◽  
Akihito Kawazoe ◽  
Toshiki Masuishi ◽  
...  

57 Background: FOLFOXIRI plus bevacizumab (BEV) is regarded as the standard of care for selected patients (pts) with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea. The AXEPT phase III study showed that the modified capecitabine (CAP) + irinotecan (IRI) + BEV (CAPIRI+BEV) [CAP 1600 mg/m2, IRI 200 mg/m2, and BEV 7.5 mg/kg q3wk] treatment was non-inferior to FOLFIRI+BEV, with a lower incidence of hematologic toxicity. We hypothesized that the modified CAPIRI combined with oxaliplatin (OX) and BEV (CAPOXIRI+BEV) would be more feasible than FOLFOXIRI+BEV, without compromising efficacy. Methods: The QUATTRO-II study is an open-label, multicenter, randomized phase II study. In Step 1, the recommended doses (RD) of OX and IRI were investigated as a safety lead-in. In Step 2, pts are randomized to either the RD of CAPOXIRI+BEV or FOLFOXIRI+BEV. In Step 1, four dose levels of CAPOXIRI (fixed dose of CAP 1600 mg/m2 and BEV 7.5 mg/kg plus escalated or de-escalated doses of OX and IRI, q3wk) were investigated in a 3+3 manner. A dose level of ≤ 2/6 of dose-limiting toxicity (DLT) cases was expected as the RD. Results: A total of 9 pts (3 at Level 0, 6 at Level 1) were included in Step 1. The baseline characteristics were as follows: the median age was 62 years; 6 were male; 6 presented with a left-sided tumor; 8 had a performance status of 0; all wild type/ RAS mutant/ BRAF V600E mutant were 8/1/0; and UGT1A1 wild type/*6 single hetero/*28 single hetero were 7/0/2. In Level 0 (IRI 200 mg/m2, OX 100 mg/m2), one grade 4 neutropenia and one grade 3 anorexia were observed, but without DLT. In Level 1 (IRI 200 mg/m2, OX 130 mg/m2), two grade 4 neutropenia and one grade 3 colitis were observed, with 1 DLT (febrile neutropenia) case, fully recovered without G-CSF administration. No treatment-related deaths were observed. Although dose modifications were needed in 4 of the 6 pts, no further safety concerns related to treatment continuity were observed in the 2nd or subsequent cycles. Thus, we determined that the dose administered in Level 1 is the RD for Step 2. According to the preliminary efficacy results at 8 weeks after initiating study treatment, 6 pts achieved a partial response (2 in Level 0 and 4 in Level 1). Conclusions: The RD of CAPOXIRI+BEV was 200 mg/m2 IRI, 130 mg/m2 OX, 1600 mg/m2 CAP, and 7.5mg/kg BEV. The randomized phase II Step (Step 2) of QUATTRO-II is ongoing. Clinical trial information: NCT04097444.


2016 ◽  
Vol 9 (3) ◽  
pp. 1279-1301 ◽  
Author(s):  
Rosemary Munro ◽  
Rüdiger Lang ◽  
Dieter Klaes ◽  
Gabriele Poli ◽  
Christian Retscher ◽  
...  

Abstract. The Global Ozone Monitoring Experiment-2 (GOME-2) flies on the Metop series of satellites, the space component of the EUMETSAT Polar System. In this paper we will provide an overview of the instrument design, the on-ground calibration and characterization activities, in-flight calibration, and level 0 to 1 data processing. The current status of the level 1 data is presented and points of specific relevance to users are highlighted. Long-term level 1 data consistency is also discussed and plans for future work are outlined. The information contained in this paper summarizes a large number of technical reports and related documents containing information that is not currently available in the published literature. These reports and documents are however made available on the EUMETSAT web pages and readers requiring more details than can be provided in this overview paper will find appropriate references at relevant points in the text.


Author(s):  
Carla Cattadori ◽  
Andrea Giachero ◽  
Claudio Gotti ◽  
Matteo Maino ◽  
Gianluigi Pessina
Keyword(s):  
Phase Ii ◽  

Electronics ◽  
2021 ◽  
Vol 10 (17) ◽  
pp. 2060
Author(s):  
Na Bai ◽  
Liang Wang ◽  
Yaohua Xu ◽  
Yi Wang

In this paper, we present a new digital baseband processor for UHF tags. It is a low-power and low-voltage digital circuit and adopts the Chinese military standard protocol GJB7377.1. The processor receives data or commands from the RF front-end and carries out various functions, such as receiving and writing data to memory, reading and sending memory data to the RF front-end and killing tags. The processor consists of thirteen main sub-modules: TPP decoding, clock management, random number generator, power management, memory controller, cyclic redundancy check, FM0 encoding, input data processing, output data processing, command detection module, initialization module, state machine module and controller. We use ModelSim for the TPP decoding simulation and communication simulation between tag and reader, and the simulation results meet the design requirements. The processor can be applied to UHF tags and has been taped out using a TSMC 0.18 um CMOS process.


2020 ◽  
Author(s):  
Christopher Mccullough ◽  
Tamara Bandikova ◽  
William Bertiger ◽  
Carmen Boening ◽  
Sung Byun ◽  
...  

<p>The Gravity Recovery and Climate Experiment Follow-On (GRACE-FO), launched in May 2018, provides invaluable information about mass change in the Earth system, continuing the legacy of GRACE. Fundamental requirements for successful mass change recovery are precise orbit determination and inter-satellite ranging, determination of the relative clock alignment of the ultra-stable oscillators (USOs), precise attitude determination, and accelerometry. NASA/Caltech Jet Propulsion Laboratory is the official Level-1 data processing and analysis center, and is currently processing software version 04. Here we present analysis of the aforementioned GRACE-FO sensor data, as well a preview of an upcoming GRACE reprocessing, and a discussion of measurement performance.</p>


1998 ◽  
Author(s):  
Sumiyuki Nishida ◽  
Jun Hachiya ◽  
Ken Matsumoto ◽  
Hiroyuki Fujisada ◽  
Masatane Kato

1995 ◽  
Author(s):  
Hiroyuki Fujisada ◽  
Hiroshi Watanabe
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document